Published on 29th August 2012
Angel Biotechnology has signed an agreement with arGentis Pharmaceuticals that could see it manufacture the firm’s ARG201 drug, a treatment for the life-threatening autoimmune disease, systemic sclerosis. Angel’s stock rose 6.6% in morning trading.
URL: http://www.digitallook.com/dl/news/story/20325944/...